Summit’s star asset is the PD-1/VEGF bispecific ivonescimab, which this week produced promising survival data from a late-stage global trial in non-small cell lung cancer. The FDA review is ongoing with a decision expected by Nov. 14.

Original title: “Summit has less than a year of cash runway left as PD-1/VEGF verdict nears”

The NCI seeks research co-development partners or licensees for NPM1 Mutation-Specific T Cell Receptors for Targeted Treatment of AML.

Original title: “Government Owned Invention Available for License: Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia (AML)”

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an AAV2-based delivery system or an eyedrop formulation to deliver a Pigment Epithelium- Derived Factor (PEDF) peptide as a gene-agnostic approach to treating inherited retinal diseases.

Original title: “Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration”

Roche has 19 investigational medicines that could launch by 2030—and even if not all of them make it to market, the company is “well set-up for growth into the next decade,” CEO Thomas Schinecker said on the pharma’s Q2 earnings call.

Original title: “Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on”

In this episode of Denatured, you’ll hear from Ester Sklarsky, principal at Sound Bioventures and João Ribas, partner at Novo Holdings Seed Investments. In this episode, we explore the diverging trajectories of Nordic biotech and what it will take for the region, including Norway and Finland, to compete more cohesively on the global stage. .

Original title: “Nordic biotech’s next act: From fragmentation to global force”

With fewer biopharmas making or planning workforce reductions so far year over year, layoff round size and M&A impact on headcounts will likely shape the number of employees who are ultimately on the chopping block.

Original title: “Biopharma layoffs must double in H2 for 2026 to match 2025 cuts”

With the stakes for successful launches high, and demand for commercial roles increasing, biopharmas must thoughtfully approach not only hiring but also retention. During a BioSpace webinar, experienced commercial leaders and a recruiter discussed the challenges employers face and how to tackle them.

Original title: “Make or break: commercial hires critical for success”

The National Center for Advancing Translational Sciences, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this Notice to Modala Bio, Inc. (Modala), headquartered in Delaware.

Original title: “Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS”

This webinar provides an assessment of recent job market activity across biopharma and explores how companies approaching commercial readiness or building out sales and marketing teams can navigate today’s hiring trends.

Original title: “Webinar: From Clinical to Commercial: Talent Strategies for Biopharma Growth”

The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker into oncology.

Original title: “GSK lung cancer drug gets speedy approval following $10.6B deal”